Videos

In an interview with CURE®, Dr. Lawrence An discusses how expressive writing can be a tool to reduce stress in patients with cancer.

It's easy to get lost in the statistics of survivorship, but it's important for newly diagnosed patients with cancer to remember that they are not a statistic.

In a recent trial, the addition of chemotherapy to endocrine therapy showed clinical benefit in premenopausal women with lymph node-positive, HR-positive, HER2-negative breast cancer.

View the full CURE Educated Patient Women's Cancer Summit on demand.

Watch our Acute Myeloid Leukemia Webinar where an expert panel discussed topics highly relevant to patients, caregivers and advocates right now.

Watch our Myeloproliferative Neoplasms Webinar where an expert panel discussed topics highly relevant to patients, caregivers and advocates right now.

Watch our metastatic colorectal cancer webinar where an expert panel discussed topics highly relevant to nurses as they care for patients and provide support to caregivers.

View all three sessions of the CURE Educated Patient Lung Cancer Summit here!

Street artist James Cochran gives CURE® an inside look at his newest project: a piece of art he created by applying 50,000 small dots of paint to a canvas using a lab pipette. It will be displayed in the Institute of Cancer Research’s Centre for Cancer Drug Discovery as a symbol of the creativity and commitment of the scientists who work every day to eradicate cancer.

View the full CURE®Educated Patient® Multiple Myeloma Summit here!

In an interview with CURE®, a Waldenstrom’s macroglobulinemia expert discusses the long-term benefits of the targeted combination of Imbruvica and Rituxan.

Imbruvica treatment in patients with chronic lymphocytic leukemia whose disease expressed a certain mutation elicited sustained efficacy over a median follow-up of four years, according to data from a long-term analysis.

In an interview with CURE®, lead study investigator Dr. John Mascarenhas discusses what the results of the phase 2 IMbark study could mean for the future of patients with myelofibrosis.